Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

JM9

Known as: JM-9 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryThe platinum analogues JM8 and JM9 were assigned randomly to 16 patients with pleural mesothelioma. Nine patients received… Expand
  • table 1
  • table 2
  • table 3
1992
1992
Qualitative and quantitative ultrastructural effects of the platinum compounds cisplatin (Platinol), carboplatin (JM8), and… Expand
1989
1989
Cisplatin is a backbone of any combination chemotherapy currently in use for the treatment for nonseminomatous germ cell tumors… Expand
1987
1987
The platinum complex cis-diamminedichloroplatinum(II)(cisplatin or CDDP), which is used successfully to treat various kinds of… Expand
1986
1986
Cis-diamminedichloroplatinum (cisplatin), a divalent platinum compound and cell-cycle nonspecific chemotherapeutic agent… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
1986
1986
Synthetic second generation chemotherapeutic platinum analogs are presently being tested to identify an analog with greater… Expand
1986
1986
This report describes the release of methotrexate and cis-platinum analogues JM8 and JM9 from phase transition liposomes. Large… Expand
1986
1986
We evaluated the cytotoxic and DNA cross-linking (CL) ability of four second generation platinum coordination complexes (TNO-6… Expand
Highly Cited
1985
Highly Cited
1985
Thirty-nine patients with advanced solid tumors, including 28 with ovarian cancer, were entered in a phase I-II trial of a new… Expand
1982
1982
Bis(isopropylamine)-trans-dihydroxy-cis-dichloroplatinum(IV) (CHIP or JM-9), a derivative of Cisplatin, was found to have DNA… Expand